Mizuho says Humana’s (HUM) 2026 star ratings update yesterday was disappointing while the other updates were positive. The company expects 20% of current members are enrolled in plans rated 4.0-plus stars or higher for 2026 versus 25% in 2025, the analyst tells investors in a research note. However, more importantly, Humana reaffirmed its 2025 earnings outlook reiterated the long-term earnings plan which was provided at the investor day in June, adds Mizuho. It keeps an Outperform rating on the shares with a $300 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target lowered to $245 from $315 at Barclays
- Humana’s Strategic Initiatives to Enhance Medicare Advantage Performance and Financial Margins
- Evercore says Humana’s preliminary MA Star ratings inline with expectations
- Humana Projects Strong 2025 Earnings Amidst Star Ratings Challenge
- Humana affirms 2025 adjusted EPS outlook $17.00, consensus $17.03